Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Eastham

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Investigative and Clinical Urology|July 7, 2017
Prostate cancer screeningJames Eastham
Urology|November 9, 2010
Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancerFred Saad, James Eastham
Seminars in Oncology|August 5, 2010
Maintaining bone health in prostate cancer throughout the disease continuumFred Saad, James Eastham
Urologic Oncology|October 2, 2010
What has to happen before we report radical prostatectomy outcomes of individual surgeons to the public?Andrew Vickers, James Eastham
Clinical Prostate Cancer|March 26, 2004
Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancerMichael W Kattan, James Eastham
Urologic Oncology|January 18, 2006
Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasisFred Saad, James McKiernan, James Eastham
European Urology|May 29, 2012
Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acidFred Saad, Scott Segal, James Eastham
Investigative and Clinical Urology|May 11, 2018
Outcomes of salvage radical prostatectomy following more than one failed local therapyArjun Sivaraman, Peter Scardino, James Eastham
International Journal of Urology : Official Journal of the Japanese Urological Association|February 3, 2009
Trends in radical prostatectomyJames Eastham, Yuji Tokuda, Peter Scardino
Journal of Surgical Oncology|September 10, 2022
Genitourinary tumorsHarry Herr, Pramod Sogani, James Eastham
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Investigative and Clinical Urology|July 7, 2017
Prostate cancer screeningJames Eastham
Urology|November 9, 2010
Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancerFred Saad, James Eastham
Seminars in Oncology|August 5, 2010
Maintaining bone health in prostate cancer throughout the disease continuumFred Saad, James Eastham
Urologic Oncology|October 2, 2010
What has to happen before we report radical prostatectomy outcomes of individual surgeons to the public?Andrew Vickers, James Eastham
Clinical Prostate Cancer|March 26, 2004
Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancerMichael W Kattan, James Eastham
Urologic Oncology|January 18, 2006
Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasisFred Saad, James McKiernan, James Eastham
European Urology|May 29, 2012
Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acidFred Saad, Scott Segal, James Eastham
Investigative and Clinical Urology|May 11, 2018
Outcomes of salvage radical prostatectomy following more than one failed local therapyArjun Sivaraman, Peter Scardino, James Eastham
International Journal of Urology : Official Journal of the Japanese Urological Association|February 3, 2009
Trends in radical prostatectomyJames Eastham, Yuji Tokuda, Peter Scardino
Journal of Surgical Oncology|September 10, 2022
Genitourinary tumorsHarry Herr, Pramod Sogani, James Eastham
Pageof 8